Peripheral neuropathy

EpiCept Corporation has filed a fast track designation with the US Food and Drug Administration (FDA) for its AmiKet, used for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

AmiKet is a prescription topical analgesic cream comprises of amitriptyline 4% and ketamine 2%; it is currently under late stage clinical development by EpiCept for the treatment of peripheral neuropathic pain.

The company received finalised guidance from the FDA for the Phase III clinical and nonclinical development and subsequent new drug application (NDA) filing of AmiKet on 23 January 2012.

The proposed 12-week four-arm factorial-designed Phase III clinical programme in CIPN will demonstrate AmiKet’s superiority compared with a placebo, with each of the component drugs of AmiKet, amitriptyline and ketamine.

In several Phase II studies, AmiKet has reported considerable improvements in the treatment of pain from post-herpetic neuralgia compared with gabapentin in another placebo-controlled study.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In 2011, EpiCept announced positive results from a National Cancer Institute-sponsored study investigating the efficacy and safety of AmiKet in CIPN.

The fast track programme is intended to facilitate the development and accelerate the review of drugs designed to treat serious or life-threatening conditions, as well as address unmet medical needs.

According to the FDA, products with a fast track designation receive priority review, which may reduce the standard review time by half.

EpiCept is focused on the development and commercialisation of pharmaceutical products for the treatment of cancer and pain associated with peripheral neuropathies.

 

Image: Micrograph showing a vasculitic peripheral neuropathy. Photo: Nephron.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact